• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫组织化学标志物在鉴别良恶性滤泡源性甲状腺结节中的作用。

Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

机构信息

Department of Pathology, Wayne State University, Sinai Grace Hospital/Detroit Medical Center, Detroit, Michigan, USA.

出版信息

Diagn Pathol. 2010 Jan 26;5:9. doi: 10.1186/1746-1596-5-9.

DOI:10.1186/1746-1596-5-9
PMID:20181018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2831001/
Abstract

BACKGROUND

Thyroid nodules are common among adults though only a small percentage is malignant, which can histologically mimic benign nodules. Accurate diagnosis of these thyroid nodules is critical for the proper clinical management.

METHODS

We investigated immunoexpression in 98 surgically removed benign thyroid nodules including 52 hyperplastic nodules (HN) and 46 follicular/Hurthle cell adenomas (FA), and 54 malignant tumors including 22 follicular carcinoma (FC), 20 classic papillary carcinoma (PTC), and 12 follicular variant papillary carcinoma (FVPC).

RESULTS

The staining results showed that malignant tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein significantly more than benign nodules. The sensitivity of these markers for the distinction between benign and malignant lesions ranged from 83.3% to 87%. The sensitivity of two-marker panels was not significantly different. Immunoexpression was usually diffuse and strong in malignant tumors, and focal and weak in the benign lesions.

CONCLUSION

Our findings indicate that these immunomarkers are significantly more expressed in malignant tumors compared to benign lesions and may be of additional diagnostic value when combined with routine histology.

摘要

背景

甲状腺结节在成年人中很常见,尽管只有一小部分是恶性的,但它们在组织学上可以模拟良性结节。准确诊断这些甲状腺结节对于正确的临床管理至关重要。

方法

我们研究了 98 个手术切除的良性甲状腺结节的免疫表达,包括 52 个增生性结节(HN)和 46 个滤泡/ Hurthle 细胞腺瘤(FA),以及 54 个恶性肿瘤,包括 22 个滤泡癌(FC)、20 个经典乳头状癌(PTC)和 12 个滤泡状变体乳头状癌(FVPC)。

结果

染色结果表明,恶性肿瘤的 galectin-3、HBME-1、CK19 和 Ret 癌基因蛋白表达明显高于良性结节。这些标志物用于区分良恶性病变的敏感性在 83.3%到 87%之间。两个标志物组合的敏感性没有显著差异。免疫表达在恶性肿瘤中通常是弥漫性和强阳性,而在良性病变中则是局灶性和弱阳性。

结论

我们的研究结果表明,与良性病变相比,这些免疫标志物在恶性肿瘤中表达明显更高,当与常规组织学结合使用时,可能具有额外的诊断价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/6c119f0940d0/1746-1596-5-9-20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/a78e4946e5d4/1746-1596-5-9-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/8a1206ae4feb/1746-1596-5-9-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/f9eafbcf03e8/1746-1596-5-9-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/9ca494bb17c1/1746-1596-5-9-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/2a95384410c0/1746-1596-5-9-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/69cba6234b51/1746-1596-5-9-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/f06710d9d7c9/1746-1596-5-9-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/4a4be7bb2fc7/1746-1596-5-9-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/318b793c4f09/1746-1596-5-9-9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/dcbcc8da2a4c/1746-1596-5-9-10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/1c5613b3351c/1746-1596-5-9-11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/847904c62a8e/1746-1596-5-9-12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/189139ce183a/1746-1596-5-9-13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/5d86802f7cef/1746-1596-5-9-14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/b185efd522a0/1746-1596-5-9-15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/b7c9c23d3071/1746-1596-5-9-16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/acf7783cc5cb/1746-1596-5-9-17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/ff62b54c469f/1746-1596-5-9-18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/09cb7215a5e6/1746-1596-5-9-19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/6c119f0940d0/1746-1596-5-9-20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/a78e4946e5d4/1746-1596-5-9-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/8a1206ae4feb/1746-1596-5-9-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/f9eafbcf03e8/1746-1596-5-9-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/9ca494bb17c1/1746-1596-5-9-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/2a95384410c0/1746-1596-5-9-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/69cba6234b51/1746-1596-5-9-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/f06710d9d7c9/1746-1596-5-9-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/4a4be7bb2fc7/1746-1596-5-9-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/318b793c4f09/1746-1596-5-9-9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/dcbcc8da2a4c/1746-1596-5-9-10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/1c5613b3351c/1746-1596-5-9-11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/847904c62a8e/1746-1596-5-9-12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/189139ce183a/1746-1596-5-9-13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/5d86802f7cef/1746-1596-5-9-14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/b185efd522a0/1746-1596-5-9-15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/b7c9c23d3071/1746-1596-5-9-16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/acf7783cc5cb/1746-1596-5-9-17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/ff62b54c469f/1746-1596-5-9-18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/09cb7215a5e6/1746-1596-5-9-19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6afe/2831001/6c119f0940d0/1746-1596-5-9-20.jpg

相似文献

1
Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.免疫组织化学标志物在鉴别良恶性滤泡源性甲状腺结节中的作用。
Diagn Pathol. 2010 Jan 26;5:9. doi: 10.1186/1746-1596-5-9.
2
Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.HBME-1和半乳糖凝集素-3的免疫组化表达在滤泡性甲状腺结节鉴别诊断中的应用
Pathol Res Pract. 2014 Dec;210(12):971-8. doi: 10.1016/j.prp.2014.06.010. Epub 2014 Jun 27.
3
Immunohistochemical diagnosis of papillary thyroid carcinoma.甲状腺乳头状癌的免疫组织化学诊断
Mod Pathol. 2001 Apr;14(4):338-42. doi: 10.1038/modpathol.3880312.
4
Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.滤泡性甲状腺病变的病理诊断挑战。
Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3365-3376. doi: 10.31557/APJCP.2021.22.10.3365.
5
[Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].[细胞角蛋白19、半乳糖凝集素-3和HBME-1在甲状腺病变中的表达及其鉴别诊断]
Zhonghua Bing Li Xue Za Zhi. 2004 Jun;33(3):212-6.
6
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.半乳糖凝集素-3、人鼠杂交瘤单克隆抗体-1、细胞角蛋白19、高分子量细胞角蛋白、细胞周期蛋白D1和p27(kip1)在甲状腺结节鉴别诊断中的诊断价值
J Korean Med Sci. 2007 Aug;22(4):621-8. doi: 10.3346/jkms.2007.22.4.621.
7
Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.HBME-1、CK19和S100在各种甲状腺病变中的鉴别诊断意义。
Malays J Pathol. 2017 Apr;39(1):55-67.
8
Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.超声风险评估联合半乳糖凝集素-3、c-MET、HBME-1 和 CK19 分子标志物在良恶性甲状腺结节诊断中的应用。
Pathol Oncol Res. 2019 Jul;25(3):1075-1081. doi: 10.1007/s12253-018-0485-6. Epub 2018 Oct 25.
9
Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.细胞周期蛋白D1在恶性潜能不确定的高分化甲状腺肿瘤中的表达
Diagn Pathol. 2015 Apr 18;10:32. doi: 10.1186/s13000-015-0262-8.
10
Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.联合甲状腺过氧化物酶、半乳糖凝集素-3、CK19 和 HBME-1 的免疫组化在甲状腺肿瘤鉴别诊断中的应用。
APMIS. 2012 May;120(5):368-79. doi: 10.1111/j.1600-0463.2011.02842.x. Epub 2011 Nov 19.

引用本文的文献

1
Utility of the Growth Differentiation Factor-15 in the Differential Diagnosis of Follicular-Patterned Lesions of the Thyroid on Cytopathologic and Histopathologic Samples.生长分化因子-15在甲状腺滤泡样病变细胞病理学和组织病理学样本鉴别诊断中的应用
Cureus. 2023 Sep 29;15(9):e46206. doi: 10.7759/cureus.46206. eCollection 2023 Sep.
2
Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions.HBME-1 和 TROP-2 在一些滤泡源性甲状腺病变中的免疫组化表达。
Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2305-2311. doi: 10.31557/APJCP.2023.24.7.2305.
3
Cytokeratin 19 (CK19) expression by thyroid neoplasms in a Nigerian tertiary health centre.

本文引用的文献

1
Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma.甲状腺滤泡性病变诊断中具有乳头状癌核特征不典型的专家间及专家内变异。
Am J Clin Pathol. 2008 Nov;130(5):736-44. doi: 10.1309/AJCPKP2QUVN4RCCP.
2
Papillary thyroid carcinoma: a root-and-branch rethink.甲状腺乳头状癌:彻底的重新思考。
Am J Clin Pathol. 2008 Nov;130(5):683-6. doi: 10.1309/AJCPBF63BWMCYSLW.
3
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.
尼日利亚一家三级保健中心的甲状腺肿瘤中细胞角蛋白 19(CK19)的表达。
Pan Afr Med J. 2023 Apr 14;44:176. doi: 10.11604/pamj.2023.44.176.37751. eCollection 2023.
4
Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.免疫组织化学在甲状腺肿瘤的病理诊断和治疗中的应用。
Front Endocrinol (Lausanne). 2023 May 31;14:1198099. doi: 10.3389/fendo.2023.1198099. eCollection 2023.
5
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.美国头颈部学会内分泌外科分会和国际甲状腺肿瘤学会共识声明:甲状腺癌的基因突变检测——定义晚期甲状腺癌及其靶向治疗。
Head Neck. 2022 Jun;44(6):1277-1300. doi: 10.1002/hed.27025. Epub 2022 Mar 11.
6
The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.HBME-1与半乳糖凝集素-3免疫组织化学及BRAF V600E突变在甲状腺乳头状癌诊断中的联合应用
Cureus. 2021 Dec 10;13(12):e20339. doi: 10.7759/cureus.20339. eCollection 2021 Dec.
7
Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.滤泡性甲状腺病变的病理诊断挑战。
Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3365-3376. doi: 10.31557/APJCP.2021.22.10.3365.
8
Periostin expression and its supposed roles in benign and malignant thyroid nodules: an immunohistochemical study of 105 cases.骨膜蛋白在甲状腺良恶性结节中的表达及其可能作用:105 例免疫组化研究。
Diagn Pathol. 2021 Sep 25;16(1):86. doi: 10.1186/s13000-021-01146-8.
9
Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules.生物标志物在甲状腺结节芯针活检不确定样本诊断中的应用。
Virchows Arch. 2021 Nov;479(5):961-974. doi: 10.1007/s00428-021-03161-y. Epub 2021 Jul 26.
10
HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP)与其他滤泡型甲状腺病变中HBME1和CK19的表达情况
World J Surg Oncol. 2021 May 8;19(1):143. doi: 10.1186/s12957-021-02258-7.
细针穿刺细胞学检查结果不确定的滤泡性甲状腺结节手术选择中的半乳糖凝集素-3表达分析:一项前瞻性多中心研究
Lancet Oncol. 2008 Jun;9(6):543-9. doi: 10.1016/S1470-2045(08)70132-3. Epub 2008 May 19.
4
Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.CD56、P63 和 CK19 免疫组化在甲状腺乳头状癌诊断中的应用。
Diagn Pathol. 2008 Feb 6;3:5. doi: 10.1186/1746-1596-3-5.
5
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.半乳糖凝集素-3、人鼠杂交瘤单克隆抗体-1、细胞角蛋白19、高分子量细胞角蛋白、细胞周期蛋白D1和p27(kip1)在甲状腺结节鉴别诊断中的诊断价值
J Korean Med Sci. 2007 Aug;22(4):621-8. doi: 10.3346/jkms.2007.22.4.621.
6
Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.CK19、半乳糖凝集素-3、HBME-1、ERK、RET和p16的差异表达在甲状腺良性和恶性滤泡源性病变中的诊断价值:一项免疫组织化学组织微阵列分析
Endocr Pathol. 2006 Fall;17(3):225-34. doi: 10.1385/ep:17:3:225.
7
Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.甲状腺滤泡性腺瘤与甲状腺乳头状癌滤泡变异型的免疫组化鉴别
Endocr Pathol. 2006 Fall;17(3):213-23. doi: 10.1385/ep:17:3:213.
8
[Galectin-3 immunodetection in thyroid fine-needle aspirates: technical procedure and results].[甲状腺细针穿刺抽吸物中半乳糖凝集素-3免疫检测:技术操作与结果]
Ann Pathol. 2006 Oct;26(5):347-51. doi: 10.1016/s0242-6498(06)70739-8.
9
Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.HBME1、半乳糖凝集素-3、细胞角蛋白19和CITED1的诊断价值及其在具有可疑甲状腺乳头状癌特征的包膜性病变中的表达评估。
Am J Clin Pathol. 2006 Nov;126(5):700-8. doi: 10.1309/044V-86JN-2W3C-N5YB.
10
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.甲状腺细针穿刺抽吸物中半乳糖凝集素3表达作为鉴别甲状腺良恶性肿瘤诊断标志物的效用。
Indian J Pathol Microbiol. 2006 Jul;49(3):376-80.